Journal
ONCOTARGET
Volume 7, Issue 12, Pages 14366-14379Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.7321
Keywords
malignant pleural mesothelioma; AKT1; SIRT1; estrogen receptor beta
Categories
Funding
- Karo Bio Research Foundation (Huddinge, Sweden)
- Fondazione Buzzi Unicem (Casale M.to, Italy)
Ask authors/readers for more resources
In this report, we show that malignant pleural mesothelioma (MPM) patients whose tumors express high levels of AKT1 exhibit a significantly worse prognosis, whereas no significant correlation with AKT3 expression is observed. We provide data that establish a phosphorylation independent role of AKT1 in affecting MPM cell shape and anchorage independent cell growth in vitro and highlight the AKT1 isoform-specific nature of these effects. We describe that AKT1 activity is inhibited by the loss of SIRT1-mediated deacetylation and identify, by mass spectrometry, 11 unique proteins that interact with acetylated AKT1. Our data demonstrate a role of the AKT1/SIRT1/FOXM1 axis in the expression of the tumor suppressor ER beta. We further demonstrate an inhibitory feedback loop by ER beta, activated by the selective agonist KB9520, on this axis both in vitro and in vivo. Our data broaden the current knowledge of ER beta and AKT isoform-specific functions that could be valuable in the design of novel and effective therapeutic strategies for MPM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available